SINGAPORE, Nov. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has named a Clinical Evaluation Management Committee. The committee will act as a semi-independent advisory board, guiding Volition's clinical trial and validation strategy both for European CE Mark and American FDA approval processes.
"As we have had very promising results in internal lab testing on small numbers of samples for our Nucleosomics range of blood-based cancer tests, we are now starting to plan for the clinical trials concurrent with testing larger numbers of samples," says Cameron Reynolds, President and Chief Executive Officer of Volition. "The members of the Clinical Evaluation Management Committee are all experts in their respective fields and will be absolutely instrumental in helping shape our trials strategy to bring our tests to market as expeditiously as possible."
The committee, which meets monthly, is made up of four internal Volition members and three independent external advisors, who will spend up to three days each month on Volition business. The external members of the committee are as follows:
Dr. Remy von Frenckell, the Chairman, is a medical statistician with more than 20 years' experience in both the academic and corporate worlds. He has served as Associate Director Biostatistics and Data Management at Bristol Myers Squibb International Corporation and founded a statistical analysis and clinical monitoring firm, S.P.R.L. CANDOR. He also held the role of Vice-President Biostatistics, Data Management, Outcomes Research at UCB Pharma, before becoming Director of Methodology and Operations at EORTC (European Organization for Research and Treatment of Cancer). Dr. von Frenckell is a member of several scientific bodies and is widely published.
Professor Carlos Graux is a haematologist and Associate Head of Clinic, Department of Clinical Hematology, CHU Mont-Godinne (UCL), Yvoir, Belgium; as well as holding the post of Professor of Immunology at the Faculty of Namur, Belgium; and coordinator of the biobank at CHU Mont-Godinne. Professor Graux is a highly experienced researcher who serves as a principal investigator of clinical trials on acute leukemia and myelodysplastic syndrome. He is currently collaborating on research into acute leukemia with the Laboratory of Molecular Pathogenesis of Leukemia, Center for Human Genetics, University of Leuven, Belgium; and into tumor resistance to chemotherapy with the "Unite de Recherche en Biologie Cellulaire – URBC", University of Namur, Belgium. Professor Graux is widely published, including in Nature Genetics; Leukemia; Blood; Annals of Hematology; New England Journal of Medicine; and Genes, Chromosomes and Cancer.
Ludwig Everaert is a clinical trials expert with experience advising on Phase I, II, III, IV and observational trials. He has held a number of clinical research and laboratory positions and has also served as Scientific Affairs Manager at Faulding Pharmaceuticals Belgium. Mr. Everaert is currently General Manager, MPI, Zemst; he also manages a consultancy business specializing in regulatory affairs, pricing and reimbursement, medical writing, clinical trials, medical information, pharmacovigilance and pack insert readability testing. Mr. Everaert presents regularly at scientific conferences and has published many articles in scientific journals. Mr. Everaert has authored regulatory affairs documents for over 150 medicines; has contributed to pre-clinical and clinical expert reports for more than 150 products; and has written many more periodic safety updates.
Internal Volition members of the committee are Cameron Reynolds, CEO; Belgian Volition Managing Director Patrick Rousseau; Belgian Volition Chief Scientific Officer Dr. Jake Micallef; and senior scientist Dr. Marielle Herzog.
Full biographies of all committee members are available on the Volition website here: http://www.volitionrx.com/clinical-evaluation-committee.html
Volition is managed by a well-respected team with extensive experience in diagnostics and commercialization. Volition's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the US and worldwide.
Volition is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.
Forward-Looking Statements: Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRX Limited